Pharmaceuticals, Biotechnology and Life Sciences
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers…
MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) — F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and…
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech…
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its…
POTOMAC, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE: CTM) (“Castellum”, or the “Company”), a cybersecurity, electronic warfare,…
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE…
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics…
Trials are currently underway in the United States, United Kingdom and Democratic Republic of CongoPending positive results from clinical trials,…
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering…